Elevated Tacrolimus Blood Concentration Due to the Interaction with Nirmatrelvir/Ritonavir During COVID-19 Treatment: A Case Report

被引：6
|
作者：
Cordero, Carlos Guzman [1 ]
de Vicente, Maria Saez-Torres [1 ,2 ]
机构：
[1] Reina Sofia Univ Hosp, Pharm Serv, Cordoba, Spain
[2] Ave Menendez Pidal s-n, Cordoba 14004, Spain
来源：
TRANSPLANTATION PROCEEDINGS | 2023年 / 55卷 / 08期
关键词：
D O I：
10.1016/j.transproceed.2023.03.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background. Nirmatrelvir/ritonavir, a newly authorized drug for the treatment of COVID-19, is a strong CYP3A4 inhibitor that can interact with many drugs, such as tacrolimus, reducing its metabolism. The reported case is a renal transplant patient who experienced a strong increase in tacrolimus blood concentration (up to 112ng/mL, more than ten times above the target range) when treated with both drugs at the same time, which caused a neurologic condition that required hospital admission for its control and treatment. The resolution of the symptoms was rapid, but the elevation of tacrolimus concentration remained for several days, even after discontinuing both drugs. This case shows the importance of developing a protocol for managing this interaction to guarantee the efficacy and safety of treatment with nirmatrelvir/ritonavir in transplant patients.
引用
收藏
页码：1826 / 1828
页数：3
相关论文
共 50 条
  • [31] Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
    Baldi, Federico
    Dentone, Chiara
    Mikulska, Malgorzata
    Fenoglio, Daniela
    Mirabella, Michele
    Magne, Federica
    Portunato, Federica
    Altosole, Tiziana
    Sepulcri, Chiara
    Giacobbe, Daniele Roberto
    Uras, Chiara
    Scavone, Graziana
    Taramasso, Lucia
    Orsi, Andrea
    Cittadini, Giuseppe
    Filaci, Gilberto
    Bassetti, Matteo
    FRONTIERS IN MEDICINE, 2023, 9
  • [32] Nirmatrelvir increases blood tacrolimus concentration in COVID-19 patients as determined by UHPLC-MS/MS method
    Wu, Q. -G.
    Zeng, L. -Y.
    LI, F.
    Zhu, Z. -Q.
    Yin, L.
    Meng, X. -M.
    Zhang, L.
    Zhang, P.
    Jiang, X. -H.
    Ling, Y.
    Zhang, L. -J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (02) : 818 - 825
  • [33] Nirmatrelvir+ritonavir/tacrolimus interactionTacrolimus toxicity following off label use and interaction: case report
    Reactions Weekly, 2023, 1954 (1) : 373 - 373
  • [34] Clinical effectiveness and safety of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in the treatment of moderate to severe COVID-19 patients
    Shi, Ji Chan
    Chen, Xin
    Lin, Xiao Qing
    Cheng, Fang
    Zheng, Shi Lin
    Zhang, Qiang
    Wu, Te
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [35] Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS
    Qin, Fuhong
    Wang, Huiling
    Li, Meng
    Zhuo, Shengnan
    Liu, Wei
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (12) : 1321 - 1327
  • [36] Nirmatrelvir/ritonavir in covid-19 patients with haematological malignancies: A report from the epicovideha registry
    Salmanton-Garcia, J.
    Marchesi, F.
    Da Silva, Gomes M.
    Farina, F.
    Davila-Valls, J.
    Bilgin, Y. M.
    Glenthoj, A.
    Martin-Perez, S.
    Rahimli, L.
    Pagano, L.
    Cornely, O. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 20 - 20
  • [37] Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
    Salmanton-Garcia, Jon
    Marchesi, Francesco
    da Silva, Maria Gomes
    Farina, Francesca
    Davila-Valls, Julio
    Bilgin, Yavuz M.
    Glenthoj, Andreas
    Falces-Romero, Iker
    Van Doesum, Jaap
    Labrador, Jorge
    Buquicchio, Caterina
    El-Ashwah, Shaimaa
    Petzer, Verena
    Van Praet, Jens
    Schoenlein, Martin
    Dargenio, Michelina
    Mendez, Gustavo-Adolfo
    Meers, Stef
    Itri, Federico
    Giordano, Antonio
    Pinczes, Laszlo Imre
    Espigado, Ildefonso
    Stojanoski, Zlate
    Lopez-Garcia, Alberto
    Prezioso, Lucia
    Jaksic, Ozren
    Vena, Antonio
    Fracchiolla, Nicola S.
    Gonzalez-Lopez, Tomas Jose
    Colovic, Natasa
    Delia, Mario
    Weinbergerova, Barbora
    Marchetti, Monia
    de Almeida, Joyce Marques
    Finizio, Olimpia
    Besson, Caroline
    Biernat, Monika M.
    Valkovic, Toni
    Lahmer, Tobias
    Cuccaro, Annarosa
    Ormazabal-Velez, Irati
    Batinic, Josip
    Fernandez, Noemi
    De Jonge, Nick
    Tascini, Carlo
    Anastasopoulou, Amalia N.
    Dulery, Remy
    Del Principe, Maria Ilaria
    Plantefeve, Gaetan
    Papa, Mario Virgilio
    ECLINICALMEDICINE, 2023, 58
  • [38] Nirmatrelvir+ritonavir/tozinameranVaccine failure, rebound COVID-19 and off-label use: case report
    Reactions Weekly, 2022, 1933 (1) : 349 - 349
  • [39] VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19
    Cao, Zhujun
    Gao, Weiyi
    Bao, Hong
    Feng, Haiyan
    Mei, Shuya
    Chen, Peizhan
    Gao, Yueqiu
    Cui, Zhilei
    Zhang, Qin
    Meng, Xianmin
    Gui, Honglian
    Wang, Weijing
    Jiang, Yimei
    Song, Zijia
    Shi, Yiqing
    Sun, Jing
    Zhang, Yifei
    Xie, Qing
    Xu, Yiping
    Ning, Guang
    Gao, Yuan
    Zhao, Ren
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (05): : 406 - 417
  • [40] A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19
    Tomida, Takeshi
    Itohara, Kotaro
    Yamamoto, Kazuhiro
    Kimura, Takeshi
    Fujita, Kohei
    Uda, Atsushi
    Kitahiro, Yumi
    Yokoyama, Naoki
    Hyodo, Yoji
    Omura, Tomohiro
    Yano, Ikuko
    DRUG METABOLISM AND PHARMACOKINETICS, 2023, 53
12345